EP0862420A4 - Synthesis of drug nanoparticles by spray drying - Google Patents

Synthesis of drug nanoparticles by spray drying

Info

Publication number
EP0862420A4
EP0862420A4 EP96939455A EP96939455A EP0862420A4 EP 0862420 A4 EP0862420 A4 EP 0862420A4 EP 96939455 A EP96939455 A EP 96939455A EP 96939455 A EP96939455 A EP 96939455A EP 0862420 A4 EP0862420 A4 EP 0862420A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
spray drying
drug nanoparticles
nanoparticles
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96939455A
Other languages
German (de)
French (fr)
Other versions
EP0862420A1 (en
Inventor
Ulagaraj Selvaraj
Gary L Messing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of EP0862420A1 publication Critical patent/EP0862420A1/en
Publication of EP0862420A4 publication Critical patent/EP0862420A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
EP96939455A 1995-10-13 1996-10-11 Synthesis of drug nanoparticles by spray drying Withdrawn EP0862420A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US519495P 1995-10-13 1995-10-13
US5194P 1995-10-13
PCT/US1996/016417 WO1997013503A1 (en) 1995-10-13 1996-10-11 Synthesis of drug nanoparticles by spray drying

Publications (2)

Publication Number Publication Date
EP0862420A1 EP0862420A1 (en) 1998-09-09
EP0862420A4 true EP0862420A4 (en) 1999-11-03

Family

ID=21714643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96939455A Withdrawn EP0862420A4 (en) 1995-10-13 1996-10-11 Synthesis of drug nanoparticles by spray drying

Country Status (2)

Country Link
EP (1) EP0862420A4 (en)
WO (1) WO1997013503A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
GB9710604D0 (en) * 1997-05-22 1997-07-16 Nycomed Imaging As Contrast media
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
CA2217095A1 (en) * 1997-10-22 1999-04-22 Hydro-Quebec Activated interface nanocomposites prepared by mechanical grinding of magnesium hydrides and their use for hydrogen storage
DE19920555B4 (en) * 1999-05-05 2004-08-26 Cognis Deutschland Gmbh & Co. Kg Use of nanoscale metal soaps
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
WO2001045674A1 (en) 1999-12-20 2001-06-28 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP2004500975A (en) 2000-05-16 2004-01-15 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ High throughput particle generator and particle generation method using multiple nozzle spray operations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
JP2004509739A (en) * 2000-09-27 2004-04-02 ベリオン　インコーポレイテッド Immediate water-soluble capsule and method for producing the same
AU2002257116A1 (en) 2001-03-30 2002-10-15 Trustees Of Princeton University A process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
KR100463167B1 (en) * 2001-04-13 2004-12-23 주식회사 태평양 Percutaneous Controlled Releasing Material Using Nano-sized Polymeric Particles and External Application Agent Containing the Same
WO2003032959A1 (en) * 2001-10-15 2003-04-24 Bosch William H Nanoparticulate compositions comprising inorganic cores
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
ATE508735T1 (en) 2001-12-19 2011-05-15 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
RU2005103625A (en) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) PHARMACEUTICAL COMPOSITIONS OF SEMI-ORDERED MEDICINES AND POLYMERS
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0310300D0 (en) * 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10351004A1 (en) 2003-10-30 2005-05-25 Basf Ag Aqueous nanodispersion-forming formulations of active agents, especially plant protectants such as fungicides, comprise random copolymer of unsaturated sulfonic acid(s)
WO2006083326A2 (en) * 2004-08-07 2006-08-10 Cabot Corporation Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof
US7829000B2 (en) 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
MX2007011772A (en) 2005-03-23 2007-12-05 Elan Pharma Int Ltd Nanoparticulate corticosteroid and antihistamine formulations.
EP1909762A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
FR2891275B1 (en) * 2005-09-26 2007-11-16 Commissariat Energie Atomique METHOD FOR MANUFACTURING COMPOSITIONS COMPRISING NANOPARTICLES OF AN ELEMEMNT OR CHEMICAL COMPOUND DISPERSE IN AN ORGANIC MATRIX
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US7951428B2 (en) 2006-01-31 2011-05-31 Regents Of The University Of Minnesota Electrospray coating of objects
CA2641117C (en) 2006-01-31 2018-01-02 Nanocopoeia, Inc. Nanoparticle coating of surfaces
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101516357A (en) * 2006-09-22 2009-08-26 米维塔尔股份公司 Emulsions comprising rubber arabicum
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
BRPI0918332A2 (en) 2008-12-18 2015-08-11 Basf Se Aqueous dispersion, method of preparing a dispersion, use of saccharide, use of dispersion and seed
US8877746B2 (en) * 2009-08-25 2014-11-04 Cardioklne, Inc Compositions for delivery of insoluble agents
IN2012DE00674A (en) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
RU2561686C1 (en) * 2014-04-01 2015-08-27 Александр Александрович Кролевец Method of encapsulation aspirin in xanthan gum
EP3586827A1 (en) 2018-06-29 2020-01-01 Consejo Superior de Investigaciones Cientificas (CSIC) Pharmaceutical formulation with improved solubility and bioavailability
CN114886856A (en) * 2022-06-09 2022-08-12 山西辅仁恒峰药业有限公司 Preparation method and application of oseltamivir nano dry suspension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
WO1994009898A1 (en) * 1992-10-26 1994-05-11 Schwarz Pharma Ag Method of manufacturing microcapsules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) * 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US5354556A (en) * 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
WO1994009898A1 (en) * 1992-10-26 1994-05-11 Schwarz Pharma Ag Method of manufacturing microcapsules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9713503A1 *

Also Published As

Publication number Publication date
EP0862420A1 (en) 1998-09-09
WO1997013503A1 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
EP0862420A4 (en) Synthesis of drug nanoparticles by spray drying
GR3032486T3 (en) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol derivatives as pharmaceutical agents
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
GB9604759D0 (en) Spray applicator
PL322277A1 (en) Derivatives of pyrazol-4-ylobenzoyl
IL144155A (en) Process for the synthesis of dioxolane derivatives
PL324992A1 (en) Novel derivatives of 2,3-dioxotetrahydoquinoxaline
BR9611561A (en) Atomizer nozzle
PL324451A1 (en) Derivatives of diphenylmethylenepiperidine
NO975662D0 (en) Use of 1,2,4-triazole derivatives for the preparation of a drug for the treatment of cancer
SG72692A1 (en) Prodrugs of paclitaxel derivatives
GR3033414T3 (en) N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
HU9502426D0 (en) Compounds of pharmaceutical activity
HUP9900924A3 (en) Substituted 1 betha-d-arabinofuranosylcytosine derivatives and use of the same for producing pharmaceutical compositions having antitumor activity
ZA9610777B (en) Production of pigments
DE29508187U1 (en) Spray booth
EP0861422A4 (en) Fixed volume sprayer
PL327059A1 (en) Derivatives of 5-naphtalen-1-yl 1,3-dioxane, their production and therapeutic application
AP9600854A0 (en) Polymorphs of the pro drug 6 N-(L-ALA-L-ALA) - trovafloxacin
HUP9900923A3 (en) Process for the synthesis of vinyl-sulfenic acid derivatives
IL118238A0 (en) Synthesis of benzoquinolinones
GB9611150D0 (en) Atomizer
GB9504913D0 (en) Production of trialkoxypropane
GB2331014C (en) Therapeutic uses of glucan
GB9320019D0 (en) Chemical synthesis of rhodamine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990921

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 9/16 A, 6B 29B 9/00 B, 6B 29B 9/12 B, 6A 61K 9/51 B, 6A 61K 9/50 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20011115